Prologis, Inc.

PLDGP

Held by 2 specialist biotech funds

Fund Holdings

Driehaus Capital Eventide Asset Management

AI Signal

**Signal Note: Immaterial for Biotech Thesis** This position in Prologis (PLDGP), a real estate logistics REIT, represents portfolio diversification unrelated to Driehaus's biotech mandate.

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$53.9M

1 fund

Feb 17, 2026

$752K

1 fund

-99% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 5,893Value: $752K

**Signal Note: Immaterial for Biotech Thesis** This position in Prologis (PLDGP), a real estate logistics REIT, represents portfolio diversification unrelated to Driehaus's biotech mandate. The $752K position is minimal relative to a growth-focused fund and signals no biotech catalyst or therapeutic advancement.

Eventide Asset ManagementNEWFeb 13, 2026

Shares: 420,834

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AXON2 funds NVDA2 funds VEEV2 funds VCYT2 funds LBRT2 funds RMBS2 funds UNP2 funds LITE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Eventide's Prologis Entry Signals Conviction in Logistics Infrastructure** Eventide's $53.9M new position in Prologis (industrial REIT) appears strategically misaligned with its biotech-focused mandate, suggesting either portfolio diversification or potential conviction in logistics-dependent biotech supply chains (manufacturing, distribution, cold-chain infrastructure). The entry timing lacks obvious biotech catalysts, warranting clarification on whether this reflects indirect biotech exposure or strategy shift away from pure-play therapeutics.